Unresectable Breast Cancer Clinical Trials in Rennes
2 recruitingRennes, France
Showing 1–2 of 2 trials
Recruiting
Phase 2
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Institut Curie20 enrolled9 locationsNCT07193394
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732